A novel drug-eluting indwelling pleural catheter for the management of malignant effusions by Bhatnagar, Rahul et al.
                          Bhatnagar, R., Zahan-Evans, N., Kearney, C., Edey, A. J., Stadon, L. J.,
Tremblay, A., & Maskell, N. A. (2018). A novel drug-eluting indwelling
pleural catheter for the management of malignant effusions. American
Journal of Respiratory and Critical Care Medicine, 197(1), 136-138.
https://doi.org/10.1164/rccm.201701-0097LE
Peer reviewed version
Link to published version (if available):
10.1164/rccm.201701-0097LE
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via ATS at https://www.atsjournals.org/doi/10.1164/rccm.201701-0097LE. Please refer to any applicable terms
of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
 1 
 
A Novel Drug-Eluting Indwelling Pleural Catheter for the Management of Malignant 
Effusions 
 
Corresponding Author  
 
Dr Rahul Bhatnagar PhD 1,2 
Academic Clinical Lecturer 
Rahul.Bhatnagar@Bristol.ac.uk  
+44 7887997420 
 
 
Co-Authors 
 
1. Natalie Zahan-Evans BSc  2 
Pleural Research Nurse 
 
2. Christine Kearney MS 3 
Senior Principal Engineer 
 
3. Dr Anthony J Edey MB BS 2 
Consultant Radiologist 
 
4. Louise J Stadon BSc (Hons) 2 
Pleural Research Nurse 
 
5. Professor Alain Tremblay MDCM 4 
Professor of Medicine 
 
6. Professor Nick A Maskell DM 1,2 
Professor of Respiratory Medicine 
 
Author affiliations  
1. Academic Respiratory Unit 
School of Clinical Sciences, University of Bristol, Learning and Research Building, 
Level 2 
Southmead Hospital 
Bristol 
BS10 5NB 
United Kingdom 
 2 
 
 
2. North Bristol Lung Centre 
North Bristol NHS Trust 
Southmead Hospital 
Bristol 
BS10 5NB 
United Kingdom 
 
3. BD (Becton, Dickinson and Company) 
75 North Fairway Drive 
Vernon Hills 
Illinois  
60061 
United States of America 
 
4. Division of Respiratory Medicine 
Cumming School of Medicine, University of Calgary 
3330 Hospital Drive NW 
Calgary 
Alberta  
T2N 4N1 
Canada 
 
 
Funding 
The study was funded and sponsored by the device manufacturer, Becton, Dickinson and 
Company (“BD,” formerly CareFusion Ltd.) (Vernon Hills, IL, USA). The study design was 
developed jointly by the trial investigators and the Sponsor. None of the trial investigators 
have received payment for any part of the design, delivery or publication of the trial. 
 
  
 3 
 
To the Editor, 
Malignant pleural effusions (MPE) affect an estimated 150,000 people per year in the US.(1) 
Average life expectancy following diagnosis is 4-6 months.(2) Management usually involves 
either insertion of an indwelling pleural catheter (IPC) or talc pleurodesis. Talc treatment 
typically requires a hospital stay of at least four days,(3) but IPCs allow ambulatory 
management and can be inserted as a day case. IPCs, however, induce pleurodesis less 
effectively, with success rates of approximately 45% (compared to 70% for talc) at a median 
of 52 days.(4) 
A new drug-eluting IPC has recently been developed, with the aim of enhancing 
effectiveness by the addition of an established pleurodesis agent, silver nitrate, as a slow-
release coating. The total dose delivered (100mg) is considerably lower than has historically 
been given during bolus administration. The SEAL-MPE study (NCT02227732, REC 
13/WA/0379 and MHRA 2014/011/028/081/010) was a first-in-human trial designed to 
evaluate the basic safety profile of the novel silver nitrate-coated indwelling pleural catheter 
(SNCIPC) device in MPE. All patients documented informed consent and a safety data 
committee met at frequent intervals. Some of the results of this study have been previously 
reported in the form of an abstract.(5) 
The protocol and analysis plan were designed jointly by the investigators and the Sponsor. A 
prospective, unblinded, single-arm cohort design was used. Patients were recruited 
consecutively from Southmead Hospital (Bristol, UK) between July 2014 and May 2015. The 
full trial follow-up period was 60 days, with a target of ten evaluable patients. The primary 
objective was to describe the number and nature of adverse events (AE), defined as any 
untoward occurrence in a participant during the trial period. AEs were further classified as 
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being expected/unexpected, mild/moderate/severe and trial/disease/device related. A 
standard definition of a serious adverse event (SAE) was used.(6) Secondary objectives 
included assessments of pleurodesis success, patient symptoms, silver levels and 
inflammatory markers. Patients were eligible if they had a recurrent pleural effusion caused 
by proven malignancy with clinical evidence of adequately expandable lung following 
thoracentesis. 
The SNCIPC was inserted under local anaesthetic. Drainage took place daily until day 14 
post-insertion, with a reduced frequency thereafter. Patients were defined as having 
undergone successful pleurodesis once they drained ≤50mls of fluid on three consecutive 
occasions over a minimum of five days. 
All patients who were consented were included in the analysis. All trial data were available 
to the investigators and were analysed using IBM SPSS v23 (IBM Corp., Armonk, NY, USA) 
and Prism v6 (GraphPad Software, La Jolla, CA, USA). The mean age of participants was 70·3 
years (SD 11·09) with 5/10 male. They had undergone a median of 1.5 (range 1-3) 
therapeutic pleural procedures in the previous three months. Four patients were on anti-
cancer therapy, but all had developed their effusion whilst on treatment.  
A total of 69 AEs were recorded during the trial period. The majority (42/69) were related to 
underlying conditions and 17/69 were device-related. There were no unexpected adverse 
device events (UADE) recorded. Eight events were documented as serious (6/8 post-
insertion). Only one SAE was related to the trial device: chest pain requiring increased 
analgesia, extended stay, and ultimately device removal (figure 1).  
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After excluding one patient in whom non-expandable lung was only revealed after catheter 
placement, 8/9 (89%) patients met the criteria for pleurodesis during the study. The median 
time to pleurodesis was 4 days (IQR 2-6) (figure 2). All patients who achieved pleurodesis 
maintained this effect at day 28 and 60 follow-up visits. 
Patients complained of minimal chest pain at baseline, with a median VAS score of 1.5mm 
(0-4.0). This rose on day one post device insertion to a median of 36.0mm (14.0-65.0) before 
reducing to 4.0mm (0-18.0) in day seven. 
No deleterious increase in either blood or pleural fluid silver levels was identified, with peak 
median blood values noted on days 14 and 28 respectively. The peak median value for blood 
C-Reactive Protein (CRP) 103.5mg/L (56.0-142.0) was seen on day seven. 
Given the short average life expectancy of those with MPE, it is vital to minimise the impact 
of effusions on quality of life. Some authors have attempted to use a normal IPC as a 
delivery method for a chemical agent, although this approach can mandate relatively 
frequent outpatient visits.(7) The SNCIPC tested in our study, however, is the first device 
which has attempted to truly be a complete solution. Indeed, although the general concept 
of drug-eluting devices is well-established, especially in coronary artery disease,(8) the 
SNCIPC is the first drug-eluting device designed for intrapleural use.    
The relatively high number of recorded AEs was anticipated given the stringency of event 
recording and the palliative nature of the recruitment population. The SNCIPC nonetheless 
appeared to be well-tolerated, with 15/17 device-related AEs classed as mild. No cases of 
pneumonia were attributable to the device. One patient required the SNCIPC to be removed 
due to early pain, however pain is a common and expected side effect of both pleurodesis 
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and IPC insertion and can usually be controlled with simple analgesia. Indeed, a degree of 
patient discomfort would actually support the notion of the SNCIPC causing the desired 
inflammatory stimulus to cause pleurodesis.  
Of the nine patients with expandable lung, 89% achieved pleurodesis after a median of four 
days, which compares favourably with talc and is far superior to what might be expected 
with an IPC alone, even with aggressive drainage regimens or more rigorous patient 
selection.(9, 10)  
Due to the small number of patients involved, no firm conclusions can be drawn about the 
SNCIPC’s efficacy from our study. Furthermore, SEAL-MPE was undertaken in a specialist 
centre with significant pleural and clinical trial expertise available, with the frequency of 
drainage and review perhaps not easily translatable to routine practice. 
Nonetheless, the SNCIPC has the potential to represent the most important advance in the 
management of recurrent MPE since the original PleurX catheter was introduced two 
decades ago. The results of this study have subsequently led to an ongoing multicentre, 
international, randomised controlled trial which will look to more comprehensively 
investigate the efficacy of the SNCIPC device. 
  
 7 
 
REFERENCES 
1. Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-
defined region. Epidemiologic study in central Bohemia. Chest 1993; 104: 1486-1489. 
2. Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, Bintcliffe OJ, 
Boshuizen RC, Fysh ET, Tobin CL, Medford AR, Harvey JE, van den Heuvel MM, Lee 
YC, Maskell NA. Predicting survival in malignant pleural effusion: development and 
validation of the LENT prognostic score. Thorax 2014; 69: 1098-1104. 
3. Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, Davies CW, Grayez 
J, Harrison R, Prasad A, Crosthwaite N, Lee YC, Davies RJ, Miller RF, Rahman NM. 
Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for 
relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized 
controlled trial. JAMA : the journal of the American Medical Association 2012; 307: 
2383-2389. 
4. Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in 
adults with malignant pleural effusions: a systematic review. Journal of general 
internal medicine 2011; 26: 70-76. 
5. Bhatnagar R, Zahan-Evans N, Kearney C, Tremblay A, Maskell N. The SEAL-MPE Trial: A 
Phase I Safety Evaluation Of A Novel Silver Nitrate Coated Indwelling Pleural 
Catheter. Am J Respir Crit Care Med 2016; 193: A7813. 
6. European Medicines Agency. Clinical Safety Data Management: Definitions and Standards 
for Expedited Reporting. London, UK; 1995. 
7. Ahmed L, Ip H, Rao D, Patel N, Noorzad F. Talc pleurodesis through indwelling pleural 
catheters for malignant pleural effusions: retrospective case series of a novel clinical 
pathway. Chest 2014; 146: e190-194. 
 8 
 
8. Stefanini  GG, Holmes  DRJ. Drug-Eluting Coronary-Artery Stents. New England Journal of 
Medicine 2013; 368: 254-265. 
9. Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural 
effusions in patients fit for pleurodesis. Eur Respir J 2007; 30: 759-762. 
10. Wahidi MM, Reddy C, Yarmus L, Feller-Kopman D, Musani A, Shepherd RW, Lee H, 
Bechara R, Lamb C, Shofer S, Mahmood K, Michaud G, Puchalski J, Rafeq S, Cattaneo 
SM, Mullon J, Leh S, Mayse M, Thomas SM, Peterson B, Light RW. Randomized Trial 
of Pleural Fluid Drainage Frequency in Patients with Malignant Pleural Effusions-The 
ASAP Trial. Am J Respir Crit Care Med 2016. 
 
  
 9 
 
Figure 1 – Summary of primary outcome (adverse events) 
 
 10 
 
FIGURE 1 LEGEND: AE = Adverse Event (any untoward occurrence in a trial participant); 
SAE = Serious Adverse Event (any adverse event leading to death; which is life-
threatening; leading to hospital admission or extension of hospital stay; causing 
persistent disability or incapacity) 
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Figure 2 – Kaplan-Meier survival curve of pleurodesis success in all ten trial patients 
 
FIGURE 2 LEGEND: The majority of participants achieved the pre-defined pleurodesis criteria 
at a median of 4 days. The study was designed such that catheters could not be removed 
before day 10 post-insertion unless felt to be clinically indicated by the Chief Investigator.  
 
 
